| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.89.3.959 |
| P698 | PubMed publication ID | 8124836 |
| P2093 | author name string | Waters D | |
| Le May M | |||
| Lespérance J | |||
| Gladstone P | |||
| Boccuzzi SJ | |||
| Higginson L | |||
| Kimball B | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 959-968 | |
| P577 | publication date | 1994-03-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. | |
| P478 | volume | 89 |
| Q37268111 | A cerebrovascular perspective of atherosclerosis |
| Q46099521 | A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials |
| Q41032297 | A new look at coronary angiograms: plaque morphology as a help to diagnosis and to evaluate outcome |
| Q34334884 | A new statin: a new standard. |
| Q44985420 | A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study |
| Q73120700 | A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT St |
| Q41210727 | Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors |
| Q41214587 | Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention |
| Q42544246 | Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). |
| Q41697370 | Aggressive medical therapy for the prevention and treatment of coronary artery disease |
| Q31101617 | All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. |
| Q37427239 | An emerging paradigm in atherosclerosis: focus on subclinical disease |
| Q36675401 | Analysis of angiographic trial data in women. |
| Q73045633 | Angiographic predictors of neointimal thickening after successful coronary wall healing following percutaneous revascularization |
| Q43670629 | Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial |
| Q37765188 | Atherosclerotic plaque regression: fact or fiction? |
| Q41454232 | Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias |
| Q74648364 | B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS) |
| Q41386366 | Barriers to lifestyle change, and the need to develop an integrated approach to prevention |
| Q35585971 | Barriers to preventive interventions for coronary heart disease |
| Q72623689 | Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels |
| Q34122524 | Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol |
| Q47675542 | Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials |
| Q41036925 | Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal |
| Q35734332 | Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins |
| Q73048100 | CAPRIE trial |
| Q74143838 | Can single photon emission computed tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia? |
| Q34068766 | Cardiac risk stratification: Role of the coronary calcium score |
| Q40368068 | Cholesterol in patients with coronary heart disease: how low should we go? |
| Q34224519 | Clinical context: current concepts of coronary heart disease management |
| Q40482684 | Clinical perspectives on primary and secondary prevention of coronary atherosclerosis |
| Q33646070 | Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols |
| Q44009755 | Clinical trial endpoints: angiograms, events, and plaque instability |
| Q34093408 | Clinically relevant differences between the statins: implications for therapeutic selection |
| Q35838501 | Combined antihypertensive and lipid-lowering treatment |
| Q40921761 | Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia |
| Q53655656 | Comparison of coronary artery calcium progression by electron beam computed tomography and angiographically defined progression. |
| Q73256695 | Contemporary cardiac rehabilitation services |
| Q40843204 | Current and future treatment of hyperlipidemia: the role of statins |
| Q33993678 | Current, new and future treatments in dyslipidaemia and atherosclerosis |
| Q33485663 | Currently available hypolipidaemic drugs and future therapeutic developments |
| Q41220381 | Delayed progression or regression of coronary atherosclerosis with intensive risk factor modification. Effects of diet, drugs, and exercise |
| Q34714444 | Disparity between angiographic regression and clinical event rates with hydrophobic statins |
| Q34552563 | Documenting regression of atherosclerosis: practical approaches in drug development |
| Q41154308 | Drug therapy of severe hypercholesterolemia in patients with coronary artery disease |
| Q34663551 | Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia |
| Q30453685 | Effect of butyrolactone I on the producing fungus, Aspergillus terreus |
| Q53535880 | Effect of exercise-based cardiac rehabilitation on non-culprit mild coronary plaques in the culprit coronary artery of patients with acute coronary syndrome. |
| Q34088640 | Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group |
| Q73227459 | Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group |
| Q71774494 | Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study |
| Q72737491 | Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group |
| Q35872973 | Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts |
| Q73606171 | Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]) |
| Q71857077 | Effects of flwastatin on growth of porcine and human vascular smooth muscle cells in vitro |
| Q73356327 | Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury |
| Q78004709 | Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L- |
| Q34990662 | Effects of lipids on thrombotic mechanisms in atherosclerosis |
| Q51051675 | Effects of statins on restenosis after coronary stent implantation. |
| Q34644974 | Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial |
| Q34142678 | Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials |
| Q33815841 | Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke |
| Q40950297 | Efficacy of interventions designed to inhibit the progression of coronary atherosclerosis |
| Q52881005 | Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. |
| Q33899261 | Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity |
| Q53915752 | Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. |
| Q51965414 | Global cardiovascular risk : the role of plasma lipids. |
| Q36782743 | Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients |
| Q32050110 | HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data |
| Q34236671 | HMG-CoA reductase inhibitors |
| Q73936731 | Has interest in secondary prevention increased among physicians after the 4S study? |
| Q37350172 | High-density lipoprotein/apolipoprotein A-I infusion therapy |
| Q41274481 | Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate |
| Q33646056 | Impact of dyslipidaemia. Lessons from clinical trials |
| Q40238908 | Impact of statins on atherosclerotic plaque |
| Q45031014 | Impact of statins on risk of stroke: a meta-analysis |
| Q41480230 | In vivo imaging of leukocyte recruitment to the atheroprone femoral artery reveals anti-inflammatory effects of rosuvastatin |
| Q47889421 | Influence of bilateral oophorectomy upon lipid metabolism |
| Q44054756 | Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). |
| Q77709255 | Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial |
| Q42547016 | Is calcium the key for the assessment of progression/regression of coronary artery disease? |
| Q41386381 | Lessons from coronary atherosclerosis "regression" trials |
| Q43610532 | Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin |
| Q33944796 | Lipid lowering improves endothelial functions |
| Q41386341 | Lipid lowering: the case for identifying and treating the high-risk patient |
| Q40440931 | Lipid risk factors and the regression of atherosclerosis |
| Q71774515 | Lipid-lowering interventions in angiographic trials |
| Q34054446 | Lipid-lowering therapy after coronary revascularization |
| Q32067070 | Lipid-lowering therapy after coronary revascularization: the interventional cardiologist's perspective |
| Q33746602 | Lipids and vascular disease: what we do and do not know |
| Q43919588 | Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia |
| Q34207135 | Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors |
| Q35091923 | Lovastatin extended release: a review of its use in the management of hypercholesterolaemia |
| Q60723119 | Lovastatin maintains nitric oxide—but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery |
| Q77569194 | Low-density lipoproteins and risk for coronary artery disease |
| Q42856073 | Lower patients' cholesterol now |
| Q35215088 | Managing the spectrum of dyslipidemia in primary care |
| Q44567975 | Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial |
| Q71443460 | Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro |
| Q38503919 | Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease |
| Q74823705 | New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease |
| Q52531869 | New insights into plaque stabilisation by lipid lowering. |
| Q35860020 | Novel HDL-directed pharmacotherapeutic strategies |
| Q28195424 | Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes |
| Q34373712 | Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation |
| Q34773911 | Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin |
| Q71827242 | Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events |
| Q77983394 | Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators |
| Q77291934 | Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile |
| Q72564453 | Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) |
| Q37879977 | Present status of HMG reductase inhibitors in treatment of dyslipidemia |
| Q41206546 | Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors |
| Q77714696 | Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention |
| Q33859347 | Prevention of coronary heart disease. Part I. Primary prevention |
| Q41440536 | Prevention of primary event. Ischemic stroke risk detection and reduction. |
| Q35077221 | Prevention of stroke and dementia with statins: Effects beyond lipid lowering |
| Q35696516 | Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders |
| Q43232124 | Purification and Characterization of a Lovastatin Esterase from Clonostachys compactiuscula |
| Q34552571 | Quantitative coronary angiography in regression trials: a review of methodologic considerations, endpoint selection, and limitations |
| Q40421165 | Range of serum cholesterol values in the population developing coronary artery disease |
| Q53347765 | Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. |
| Q34107307 | Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk |
| Q36913015 | Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review |
| Q78245297 | Relation between low-density lipoprotein cholesterol and thoracic aortic atherosclerosis |
| Q74596935 | Relation of angiographic and ultrasound assessment of plaque progression to clinical outcomes |
| Q77390977 | Relation of clinical benefit to metabolic effects in lipid-lowering therapy |
| Q71774498 | Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study |
| Q45972408 | Reversal of atherosclerosis with therapy: update of coronary angiographic trials. |
| Q41171305 | Review of the major intervention trials of lowering coronary artery disease risk through cholesterol reduction |
| Q36823012 | Role of imaging end points in atherosclerosis trials: focus on intravascular ultrasound |
| Q30946248 | Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris |
| Q35961612 | Rosuvastatin reduces neointima formation in a rat model of balloon injury |
| Q41633477 | Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis |
| Q51499146 | Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene. |
| Q42390248 | Should we treat hypercholesterolaemia in patients over 65? |
| Q77896411 | State-of-the-art update and review: clinical trials of lipid-lowering agents |
| Q73226848 | Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease |
| Q35100297 | Statin treatment and progression of atherosclerotic plaque burden |
| Q51484977 | Statins for treating stable angina: can statins improve the plaque morphology and angina? |
| Q28200294 | Statins in the treatment of chronic heart failure: a systematic review |
| Q85034434 | Statins moderate coronary stenoses but not coronary calcification: Results from meta-analyses |
| Q71520573 | Statins prevent coronary heart disease |
| Q40067800 | Strategies to reverse atherosclerosis: an imaging perspective |
| Q36398725 | Studying coronary plaque regression with IVUS: a critical review of recent studies. |
| Q37981833 | Targeting tumor cell metabolism with statins. |
| Q37098879 | Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature |
| Q24796000 | The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst |
| Q40274666 | The ASTEROID trial: coronary plaque regression with high-dose statin therapy. |
| Q33571213 | The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences |
| Q36839344 | The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia |
| Q41135818 | The arterial wall: a new pharmacological and therapeutic target |
| Q35137013 | The complex interplay between cholesterol and prostate malignancy |
| Q45985684 | The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. |
| Q33818141 | The evolving role of statins in the management of atherosclerosis |
| Q36867018 | The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease |
| Q40421170 | The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group |
| Q47764127 | The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events |
| Q43707849 | The reversal of the inhibition on lipids synthesis by L-659,699 in arterial smooth muscle cells cultures |
| Q35692031 | The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy |
| Q41526401 | The secondary prevention of coronary artery disease |
| Q37576100 | The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease |
| Q74460431 | Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy |
| Q34491358 | Treating lipid abnormalities in patients with type 2 diabetes mellitus |
| Q34336846 | Treatment of dyslipidemia in pre- and postmenopausal women with and without known atherosclerotic cardiovascular disease |
| Q47986997 | Use of Statins for Secondary Prevention |
| Q34300585 | Use of statins in CNS disorders |
| Q71970830 | Validation of coronary artery saphenous vein bypass graft diameter measurements using quantitative angiography |
| Q40421178 | What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? |
| Q34767394 | Who should receive HMG CoA reductase inhibitors? |
| Q40838703 | Women, dyslipoproteinemia, and estrogens |
| Q74639211 | [Therapy with CSE inhibitors--more than lipid lowering?] |
Search more.